Newtown PA – December 8, 2014 – Helius Medical Technologies (CSE: HSM) (“HMT”, “Helius” or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 950,000 shares of the Company, to directors, officers, and consultants of the Company.
All options are subject to any earlier termination in accordance with their terms. 450,000 options vest immediately upon grant and are exercisable at a price of CAD $2.92. Another 100,000 options are also exercisable at a price of CAD $2.92, with one-third of such options vesting on the date of grant and another one-third vesting on first and second anniversary of the date of grant. The remaining 400,000 options are exercisable at a price of CAD $2.96, with one-quarter of such options vesting on the date of grant and another one-quarter vesting on each six-month anniversary of the date of grant.
The Company is also pleased to announce that further to its news release dated November 3, 2014, Dr. Catherine Cho has joined the Company’s Scientific and Medical Advisory Board. Dr. Cho is an Assistant Professor of Neurology at the Icahn School of Medicine at Mount Sinai and brings to the board her extensive experience with gait and balance impairment across multiple neurological diseases. She also has experience with deep brain stimulation in Parkinson’s disease, tremors, and dystonia.
Dr. Jonathan Sackier, Chairman of the Scientific Advisory Board and Chief Medical Officer, adds “Dr. Cho is an accomplished and forward-thinking clinician working at one of the most highly-respected medical institutions in the country. We are thrilled to have her thoughtful participation on the Scientific Advisory Board.”
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
- Corporate Contact: Phil Deschamps, 614-596-2597 or email@example.com
- Investor Relations Contact: 778-588-7144 or firstname.lastname@example.org
- Media Contact: Becky Kern, 914-772-2310 or email@example.com
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.